Because a B2M antibody was part of the IMC panel (Supplementary Table 5), we could assess that a B2M truncating mutation led to no protein expression in the tumor compared with a widespread B2M expression in CRCs with wild-type B2M (Figure 2F). The gene discussed is B2M; the disease is neoplasm.